🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Immunosensitivity cuts across mismatch repair status in colorectal cancer Our preview article on the recent Acha-Sagredo et al. has been published today in Cancer Cell. shorturl.at/uJ8av

Wim Laleman emphasised the critical role of endoscopy in the palliative management of malignant bile duct strictures at #LiverCancerSummit. While endoscopic drainage improves quality of life and survival, a multidisciplinary approach is essential. Laleman showcased advanced

First patient dosed worldwide today in #AZUR4 at UZ Leuven 🌎🏅 While the exact relevance of #pCR as a surrogate endpoint remains an important question for debate, still, very curious where we will land. Time will tell. ⏰🤔 #pMMR #MSS #CRC Leuven Kankerinstituut

🔥🔥 Highly recommended! In person 👩‍⚕️or online👨‍💻

Fine, here we go. First let's start with some baseline expectations. Pancreatic cancer is scary, 5y survival is ~10%. So if you see a trial with an apparent survival asymptote at ~50% then certainly *something* is happening, right?

🎙️ Podcast on biomarkers in #HCC - Sarah Cappuyns 🔥

I recently had a chat with Jeroen Dekervel about one of our favourite topics… Biomarkers in HCC: why we need them, and why they are so difficult to identify.. Have a listen!! 🎧 🎙️👇

‼️Our latest publication in Journal of Hepatology ‼️ ✅Response to atezo+bev in HCC is immune- vs angiogenesis-driven. ⛔️Resistance is associated with immunosuppressive myeloid cells and Notch activation. 👉Molecular subgroups define distinct clinical outcomes. journal-of-hepatology.eu/article/S0168-…

Patients with ATM, CHEK2, or PALB2 pathogenic variants had similar breast, colorectal, and pancreatic cancer mortality to the average genetically tested patient with their cancer type. ascopubs.org/doi/abs/10.120…

Interested in precision medicine and #BTC #cholangiocarcinoma? Read our paper ESMO Open! authors.elsevier.com/sd/article/S20…

#SAFIR-#ABC10, an important #ClinicalTrial in #Biliary recruiting in UK, France and Belgium (not Spain 😔) #Randomsied phase III Allows molecular profiling + discussion at a #MolecTumorBoard Explores #maintenance #targeted after Chemo+IO (x4cycles) HUGE effort - Congrats 👏🏻👏🏻

🔬 Targeted therapy in focus! Explore IDH1-mutant cholangiocarcinoma management in our new video with Prof Jeroen Dekervel , Prof Demols and Prof Geboes.

#ASCO25 DYNAMIC-III coming in with the most surprising result of the year! ctDNA adapted RCT of stage III resected colon cancer (escalation of therapy) ~ 1000 patients, 259 with ctDNA+ disease, randomized 1:1 to SOC vs escalation If ctDNA +: 5-FU -> FOLFOX FOLFOX ->

#LCSM @asco PROVE ME WRONG! Early vs Late Time-of-Day (3PM cutoff) ICI dosing in 1st-line stage IIIC-IV NSCLC: randomized trial shows near doubling of PFS (13.2 vs 6.5 mo), better OS & ORR with morning infusions. Circadian rhythm matters? Will practice change? This is the

Cannot stress enough this is a huge opportunity and a great experience ESMO - Eur. Oncology

Absolutely stunning!! This is the very role of academic clinical research. Should be explored in other cancer types as well.

💡GI Highlight from #ASCO2025! Prof Jeroen Dekervel shares key findings in GI oncology: 🧪 Nivolumab OS trend (CHECKMATE 577) 🧪 PFS benefit in LEAP-015 🧪 Early signals from GAIN in BTC 🎥 Watch now bit.ly/4mLvOXR #MediMix #Oncology #GICancer

🔥 #ASCO2025 Plenary GI In-depth! Prof Van Cutsem & Prof Jeroen Dekervel on the MATTERHORN trial: ✅ Durvalumab + FLOT = improved EFS ✅ Better tumour control, no extra toxicity ✅ Promising new standard for gastric cancer 🎥 Watch now bit.ly/4mLvOXR #MediMix #GastricCancer

💡GI Highlight from #ASCO2025! Prof Jeroen Dekervel shares updates on 3 promising trials in pancreatic cancer: ✔️ PAXG > FOLFIRINOX in EFS (CASSANDRA) ✔️ TTF: modest OS benefit in locally advanced disease ✔️ Elraglusib: GSK-3β inhibitor adds 3 months OS

🎥 #ASCO2025 In-Depth! Prof Eric Van Cutsem & Prof Jeroen Dekervel Dekervel on DESTINY-Gastric04: ✔️ T-DXd OS +3.3 mo vs 2L SOC ✔️ ORR 44%, ILD 13% (mostly mild) ✔️ EMA: rebiopsy not required 👀 Watch now bit.ly/4mLvOXR #MediMix #HER2 #GastricCancer #TDXd